INV-102 for the treatment of mustard gas keratopathy under BAA-18-100-SOL-00003, area of interest 5.3.

Active Definitive Contract Awarded Last action

Contract number
75A50120C00171
Awardee
Awarding agency
Obligated
$47,965,983

Award facts

Opportunity
Contract value 96% obligated
  • $47,965,983.00 Current, with exercised options
  • $50,147,758.00 Potential, with all options
Completion date 61% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
GRANDVIEW, OH 43212, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00013 · Add additional funding to clin 0003 and extend the period of performance (POP) of clin 0003 $9,000,000
Supplemental Agreement for work within scope P00012 · Add additional funding to clin 0001, extend the POP of performance of clin 0001, update far and HHS clauses, and update the SOW $3,641,138
Supplemental Agreement for work within scope P00011 · Invirsa - exercise clin 0003/option 2; update the period of performance (POP) for clin 0001, 0002, 0003 & 0004; update budgets of clin 0003 & 0004; update… $15,293,238
Funding Only Action P00010 $1,977,664
Supplemental Agreement for work within scope P00009 $0
Supplemental Agreement for work within scope P00008 $0
Funding Only Action P00007 $1,105,313
Supplemental Agreement for work within scope P00006 $0
Exercise an Option P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Supplemental Agreement for work within scope P00002 $0
Exercise an Option P00001 $2,511,750
Original award $14,436,880
Show all 14

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a $50.1 million definitive contract to Invirsa, Inc. for advanced research and development of medical countermeasures for mustard gas keratopathy on September 28, 2020, with ultimate completion on September 4, 2030. The contract operates under cost-sharing pricing with no set-aside.

The originating solicitation is BAA-18-100-SOL-00003, Area of Interest 5.3, a Broad Agency Announcement from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The award reflects additional funding added to CLIN 0003 and an extension to its period of performance.

Place of performance is Grandview, OH. Government-invoiced labor in FY2024 was $3.2 million across 5.3 FTEs and 10,964 contractor hours, with a derived hourly rate of $294.74. Invirsa self-performed all reported hours with no subcontractors. The derived hourly rate declined from $475.79 in FY2021, reflecting a reduction in per-hour cost posture over the contract's execution.

Quick answers

Who was awarded contract 75A50120C00171?

75A50120C00171 was awarded to Invirsa, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 28, 2020.

How much is contract 75A50120C00171 worth?

The government has obligated $47,965,983 on 75A50120C00171. Its potential value, with all options, is $50,147,758.

Was contract 75A50120C00171 competed?

The extent of competition for 75A50120C00171 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login